Replies to post #579 on Ariad Pharmaceuticals Inc fka ARIA

[BTH]

How did '464 work out for shareholders, Don?

All your arguments sounds very familiar to other arguments made when '464 was on the petri dish and it was hailed as the next Gleevec.

8 years later (?) the analog to '464, '534, still hasn't been approved. Yes, there sure is overwhelming evidence that '534 will be a major success, but only since it was proven to be so after dosing dozens of patients - - - not smearing a sample on a dish or putting a pellet in a mouse, like they are doing with '113, or '464.